US medical device maker partners with GenesisCare on cancer research and treatment
23 Nov 2018
Varian and GenesisCare have signed a memorandum of understanding (MoU) to form a strategic partnership for cancer care research and to increase access to advanced cancer care across Australia.
Varian, a leading manufacturer of medical devices and software, and GenesisCare, Australia’s largest private provider of cancer care, will work together to roll out of a range of hardware and software over the following five years.
‘Varian is delighted to be partnering with GenesisCare to increase Australian patient access to our radiation technology, and ultimately improve the cancer treatment experience, and hopefully outcomes, for those in need,’ says Chris Cowley, Varian Australasia Managing Director.
‘We are dedicated to combining the ingenuity of people with the power of data and technology to achieve new victories against cancer.’
Radiation therapy is a highly effective cancer treatment that is under-utilised in Australia, says radiation oncologist Associate Professor Peter O’Brien, GenesisCare’s Australian Chief Medical Officer, in a company media release.
‘The advances in radiation therapy technology in recent years have been quite phenomenal and we’re now able to use platforms that give us pinpoint accuracy and streamlined access to patient data,’ he says. ‘This helps us deliver better outcomes for our patients, which is ultimately what matters most.’
Varian and GenesisCare will also work to develop other treatment monitoring solutions in molecular targeted radiation (theranostics). Theranostics uses nanoscience to join diagnostic and therapeutic capabilities into a single cancer fighting agent. Utilising Varian’s expertise in image-guided technology and GenesisCare’s experience in clinical and research domains, Varian and GenesisCare will partner to develop image-guided treatment monitoring solutions in this evolving area.
Headquartered in California, Varian is a world leader in developing and delivering cancer care solutions. It has been operational in Australasia since 1999, and now employs over 70 people in the region.
GenesisCare treats people with cancer and heart disease. It employs more than 2,500 healthcare professionals and support staff across Australia, Europe and China, and sees over 160,000 patients annually at more than 130 locations. It is currently leading or participating in more than 100 clinical trials.